Blair William & Co. IL Sells 20,182 Shares of Insulet Corporation $PODD

Blair William & Co. IL decreased its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 12.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 143,373 shares of the medical instruments supplier’s stock after selling 20,182 shares during the period. Blair William & Co. IL owned 0.20% of Insulet worth $44,263,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. True Wealth Design LLC grew its stake in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the last quarter. Golden State Wealth Management LLC raised its stake in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in Insulet by 48.9% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 43 shares in the last quarter. Quent Capital LLC bought a new stake in Insulet in the third quarter worth $49,000. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of Insulet in the second quarter worth $51,000.

Wall Street Analyst Weigh In

PODD has been the subject of several analyst reports. TD Cowen downgraded Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target for the company. in a report on Monday, January 26th. Raymond James Financial dropped their price target on shares of Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Canaccord Genuity Group cut their price objective on shares of Insulet from $450.00 to $435.00 and set a “buy” rating on the stock in a research report on Wednesday, February 18th. Truist Financial reduced their price objective on shares of Insulet from $390.00 to $360.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Finally, Leerink Partners dropped their target price on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $354.57.

Insiders Place Their Bets

In related news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.39% of the stock is currently owned by company insiders.

Insulet Price Performance

NASDAQ PODD opened at $237.01 on Friday. Insulet Corporation has a one year low of $230.05 and a one year high of $354.88. The stock has a 50-day moving average of $263.52 and a 200 day moving average of $300.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The company has a market capitalization of $16.69 billion, a price-to-earnings ratio of 67.72, a PEG ratio of 1.41 and a beta of 1.42.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The firm had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. During the same quarter last year, the firm posted $1.15 EPS. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.